Author | Study typology | Duration | Dose SAMe | Administration | Primary outcome | Diagnostic criteria |
---|---|---|---|---|---|---|
Caruso 1984 [36] | SAMe vs PBO | 3Â weeks | 200Â mg/day | IM | HAM-D (21 items) | Not specified |
Kagan 1990 [37] | SAMe vs PBO | 3Â weeks | 200Â mg/day | OR | HAM-D (21 items) | DSM-III |
Berlanga 1992 [38] | SAMe + IMI vs PBO + IMI | 2 weeks | 200 mg/day | IM | HAM-D (17 items) | DSM-III-R |
Papakostas 2010 [39] | SAMe + SRI vs PBO + SRI | 6 weeks | 800 mg/day | OR | HAM-D | DSM-IV |
Delle Chiaie 2002a [40] | SAMe vs IMI | 6Â weeks | 1600Â mg/day | OR | HAM-D (21 items) | DSM-IV |
Delle Chiaie 2002b [40] | SAMe vs IMI | 4Â weeks | 400Â mg/day | IM | HAM-D (21 items) | DSM-IV |
Mischoulon 2014a [41] | SAMe vs PBO | 12 weeks | 1600–3200 mg/day | OR | HAM-D (17 items) | IDS-C ≥ 25 |
Mischoulon 2014b [41] | SAMe vs EST | 12 weeks | 1600–3200 mg/day | OR | HAM-D (17 items) | IDS-C ≥ 25 |
Sarris 2014a [42] | SAMe vs PBO | 12Â weeks | 1600Â mg/day | OR | HAM-D (17 items) | DSM-IV |
Sarris 2014b [42] | SAMe vs EST | 12Â weeks | 1600Â mg/day | OR | HAM-D (17 items) | DSM-IV |
Sarris 2018 [43] | SAMe vs PBO | 8Â weeks | 800Â mg/day | OR | MADRS | DSM-V |